Literature DB >> 9182104

Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro.

H X Xia1, M Buckley, C T Keane, C A O'Morain.   

Abstract

Susceptibilities to clarithromycin and metronidazole of 444 Helicobacter pylori isolates cultured from antral biopsies of 444 dyspeptic patients were determined by disc diffusion tests (15 mu g disc for clarithromycin, 5 mu g disc for metronidazole). Susceptibility of 46 of these isolates to erythromycin (5 mu g disc) was also tested. Minimal inhibitory concentrations (MICs) of clarithromycin for 42 selected isolates were determined by a plate dilution method. A zone diameter of 30 mm was defined as a 'cut-off' size differentiating susceptibility and resistance of the organism to clarithromycin, by comparing results obtained with the two methods. Of the 444 isolates, 424 (95.5%) were highly sensitive to clarithromycin, with zone diameters ranging from 30 to 98 mm. Twenty isolates (4.5%) were defined as resistant to clarithromycin, with zone diameters ranging between 6 and 28 mm. The incidence of clarithromycin resistance was similar in men and women and in different age groups, and was not significantly different between patients with peptic ulcer and non-ulcer dyspepsia. Among the 444 isolates, 168 (37.8%) were metronidazole resistant. There was cross resistance between clarithromycin and erythromycin, but not between clarithromycin and metronidazole. Stability of clarithromycin resistance was evaluated by the disc diffusion test and confirmed by the plate dilution method. Among the 20 clarithromycin-resistant isolates, nine (45%) reverted to be sensitive after 25 subcultures on drug-free agar. The findings in this study indicate that the incidence of clarithromycin-resistant H. pylori in untreated dyspeptic patients is low. Cross-resistance occurs between macrolides and resistance to clarithromycin in some strains is reversible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9182104     DOI: 10.1093/jac/37.3.473

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in Singapore.

Authors:  Jie-Song Hua; Ho Bow; Peng-Yuan Zheng; Yeoh Khay-Guan
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

3.  Clarithromycin resistance in Helicobacter pylori and its clinical relevance.

Authors:  Hua-Xiang Xia; Xue-Gong Fan; Nicholas J Talley
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

Review 4.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

5.  Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin.

Authors:  M I García-Arata; F Baquero; L de Rafael; C Martín de Argila; J P Gisbert; F Bermejo; D Boixeda; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland.

Authors:  E Rozynek; D Dzierzanowska; D Celińska-Cedro; J Jeljaszewicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

7.  Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori.

Authors:  F Szczebara; L Dhaenens; P Vincent; M O Husson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

8.  Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.

Authors:  M Sörberg; H Hanberger; M Nilsson; A Björkman; L E Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 9.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

10.  Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.

Authors:  M J Buckley; H X Xia; D M Hyde; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.